Shares of Sorrento Therapeutics (NASDAQ: SRNE) are up 7% mid-day after the company’s pain subsidiary, SCILEX Pharmaceuticals, released positive data regarding its lead investigational product, ZTlido™. During a recently completed comparative adhesion performance study to support the market authorization application (MAA) in the EU, ZTlido™ demonstrated superior adhesion versus the EU reference product, Versatis®. SCILEX said it plans to resubmit the New Drug Application for ZTlido™ to the FDA and the MAA to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom in the second half of 2017. “We are pleased to report our noteworthy data. We believe that the ability of ZTlido™ to outperform Versatis® in this head to head study will translate into better patient compliance and provide us with an important clinical advantage. I look forward to moving ZTlido™ closer to commercialization in the US and the EU,” SCILEX President Anthony Mack stated in the news release.
To view the full press release, visit: http://nnw.fm/j4tbW
About Sorrento Therapeutics, Inc.
Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for pain management, cancer, inflammation and autoimmune diseases. Sorrento’s lead product candidates include late-stage pain drugs, therapeutic antibodies for cancer, inflammation and autoimmune diseases, as well as clinical stage immune-cellular therapies targeting solid tumors. For more information visit www.sorrentotherapeutics.com.
NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer